orlistat in simple obesity

Last reviewed 05/2021

743 patients with BMI 28-47 were recruited.

There was an initial placebo run-in period of 4 weeks during which a mildly hypocaloric diet was commenced.

Only patients (668) who completed this run-in and who had taken more than 75% of their tablets were enrolled into the 1 year single-blind trial of orlistat in combination with a hypocaloric diet.

In the second year patient were re-randomised to orlistat or placebo in combination with a eucaloric diet (one designed to maintain a stable weight).


  • 1) Sjostrom, L, Rissanen, A, Andersen, T. et al (1998). Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet, 352, 167-72.